SEPSECS

SEPSECS (SLA/LP) is a pyridoxal phosphate (PLP)-dependent enzyme that catalyzes the terminal step of selenocysteine biosynthesis on tRNA(Sec), converting O-phosphoseryl-tRNA(Sec) to selenocysteinyl-tRNA(Sec) (PMID:19608919). It assembles as a homotetramer that engages tRNA(Sec) through the 13-base-pair acceptor-TψC arm, and tRNA binding drives a conformational change in the active site that correctly orients the tRNA-attached phosphoserine substrate — free phosphoserine is not productively positioned, making catalysis strictly tRNA-dependent (PMID:19608919). Although the tetramer carries four equivalent active sites, no more than two tRNA(Sec) molecules bind per tetramer: a vertebrate-specific C-terminal acidic α-helical extension (helix 16) occludes tRNA binding in two monomers and stabilizes the complex, and mammalian SEPSECS can bind unacylated tRNA(Sec) without an aminoacyl group, distinguishing it from its archaeal ortholog (PMID:39385655). SEPSECS oligomerizes in cells and operates within the selenocysteine biosynthesis/incorporation machinery, physically interacting with SECp43, SEPHS1, and SEPHS2 (PMID:28414460). Loss of SEPSECS in trophoblast cells reduces proliferation and induces caspase-3-dependent apoptosis, while altering progesterone and hCG secretion (PMID:23966103). Independently, SEPSECS is the primary autoantigen recognized by disease-specific SLA/LP autoantibodies in autoimmune hepatitis, with autoantigen-specific CD4+ T cells and antigen-presenting B cells driving the autoimmune response (PMID:10801173, PMID:39817450).

1. 2000 High

   Before its enzymatic function was known, SEPSECS was identified molecularly as the sole target of the SLA/LP autoantibodies that define a serologic subgroup of autoimmune hepatitis, giving the protein a clinical identity.

   Evidence Immunoscreening of cDNA expression libraries with patient sera, inhibition ELISA, and deletion-mutant epitope mapping (residues 371–409)

   PMID:10801173

   Open questions at the time

   • Did not establish the enzymatic or cellular function of the protein
   • Epitope mapping was antibody-based and did not address T cell recognition
2. 2001 Medium

   A truncated recombinant SLA/LP protein was shown to block patient reactivity to native antigen, confirming the cloned cDNA encodes a major antigenic component and noting homology to a UGA serine tRNA-protein complex protein — the first hint of a tRNA-related function.

   Evidence cDNA library immunoscreening, preabsorption/inhibition ELISA, immunoblot of E. coli-expressed recombinant protein

   PMID:11230739

   Open questions at the time

   • The tRNA-protein homology was sequence-based, not functionally demonstrated
   • Did not define the full antigenic determinant
3. 2009 High

   The crystal structure of the human SepSecS–tRNA(Sec) complex resolved the catalytic mechanism, establishing SEPSECS as the PLP-dependent enzyme that performs the final step of selenocysteine formation only when phosphoserine is tRNA-attached.

   Evidence X-ray crystallography of the SepSecS–tRNA(Sec)–phosphoserine–thiophosphate complex with in vivo and in vitro enzyme assays

   PMID:19608919

   Open questions at the time

   • Did not explain why only two of four active sites engage tRNA
   • Did not address the enzyme's interactions with the broader selenocysteine incorporation machinery
4. 2009 Medium

   Purification of the native autoantigen from human hepatic extract and mass-spectrometric identification confirmed that the endogenous SLA/LP protein is identical to the recombinant SepSecS, unifying the autoimmune-antigen and enzyme identities.

   Evidence Immune affinity chromatography, ion exchange chromatography, mass spectrometry, monoclonal antibody validation

   PMID:19683415

   Open questions at the time

   • Single-lab purification
   • Did not address why this enzyme becomes an autoimmune target
5. 2013 Medium

   Loss- and gain-of-function in trophoblast cells assigned SEPSECS a cellular role beyond housekeeping selenoprotein synthesis, linking it to proliferation, survival, and hormone secretion.

   Evidence siRNA knockdown and overexpression in JEG-3 cells with proliferation, colony formation, Annexin V/caspase-3 apoptosis, and hormone ELISA readouts

   PMID:23966103

   Open questions at the time

   • Single cell line and single lab
   • Did not determine whether the phenotype is mediated through selenocysteine biosynthesis or an independent activity
6. 2017 Medium

   Defining SEPSECS's physical partners placed it within an assembled selenocysteine biosynthesis/incorporation complex rather than acting in isolation.

   Evidence BRET in mammalian cells and co-immunoprecipitation confirming oligomerization and interactions with SECp43, SEPHS1, and SEPHS2

   PMID:28414460

   Open questions at the time

   • Interaction stoichiometry and architecture of the complex not resolved
   • Functional consequence of each interaction not tested
7. 2024 High

   Comparative structural and biochemical analysis explained the long-standing half-site occupancy puzzle, attributing the two-tRNA-per-tetramer limit and complex stability to a vertebrate-specific C-terminal helix and revealing a mammalian-specific ability to bind unacylated tRNA(Sec).

   Evidence Comparative structural and phylogenetic analysis, acylated-vs-unacylated tRNA binding assays, and C-terminal helix mutagenesis/deletion

   PMID:39385655

   Open questions at the time

   • Functional consequence of unacylated tRNA binding for cellular selenocysteine synthesis not established
   • Did not connect the structural innovation to disease relevance
8. 2025 Medium

   Identification of SepSecS-specific CD4+ T cell clones and antigen-presenting B cells demonstrated antigen-specific B–T cell collaboration in autoimmune hepatitis, advancing the autoantigen from a serologic marker to a driver of cellular autoimmunity.

   Evidence B/T cell screening, monoclonal antibody and T cell clone isolation, intracellular cytokine staining, B cell antigen-presentation assay, and liver-biopsy TCR clonotype analysis

   PMID:39817450

   Open questions at the time

   • Causal contribution of these clones to liver injury not demonstrated
   • Mechanism by which a metabolic enzyme breaks tolerance unknown

• How SEPSECS expression is controlled in human tissues and how its enzymatic role connects to its trophoblast and autoimmune phenotypes remain unresolved.
• No mammalian transcriptional/post-transcriptional regulatory mechanism established
• Link between catalytic function and disease/cellular phenotypes uncharacterized